Yang Meng, Tan Yu-Quan, Zhang Jun-Yu, Zhang Yao, Su Li-Qing, Hu Zhi-Xi, Hu Si-Yuan
School of Traditional Chinese Medicine, Hunan University of Chinese Medicine Changsha 410208, China.
Zhongguo Zhong Yao Za Zhi. 2024 Jul;49(13):3574-3582. doi: 10.19540/j.cnki.cjcmm.20240305.401.
This study aimed to investigate the therapeutic effect of Shenfu Injection on mice with chronic heart failure(CHF) and its effect on macrophage polarization. C57BL/6J mice were randomly assigned to the normal and model groups. The CHF model was established by intraperitoneal injection of isoproterenol(ISO, 7.5 mg·kg(-1), 28 d). The successful modeling was determined by asses-sing the cardiac function and N-terminal pro-brain natriuretic peptide(NT-proBNP). The modeled mice were randomly divided into the model group, Shenfu Injection group, and TAK-242 group, and were injected intraperitoneally with the corresponding drugs for 15 days. Cardiac function was evaluated using echocardiography. Hematoxylin-eosin(HE) staining was used to detect the pathomorphology. Enzyme-linked immunosorbent assay(ELISA) was used to detect the values of serum NT-proBNP, interleukin-6(IL-6), tumor necrosis factor-α(TNF-α), IL-10, and arginase 1(Arg-1). Flow cytometry was applied to detect the relative content and M1/M2 polarization of cardiac macrophages. Quantitative polymerase chain reaction(qPCR) and Western blot were used to detect the changes in the Toll-like receptor 4(TLR4)/nuclear factor-κB(NF-κB) pathway-related mRNA and protein expressions. Compared with the normal group, mice in the model group had lower values of left ventricular ejection fraction(LVEF) and left ventricular fractional shorte-ning(LVFS), higher values of left ventricular internal diastolic end-diastolic(LVIDd), left ventricular internal diastolic end-systolic(LVIDs), NT-proBNP, TNF-α, and IL-6(P<0.01); the number of macrophages increased in cardiac tissues(P<0.05), and the values of M1-F4/80+CD86+ were increased(P<0.01), while the values of M2-F4/80+CD163+ decreased(P<0.05); the mRNA and protein expressions of TLR4, myeloid differentiation factor 88(MyD88), IκB kinase α(IKKα), and NF-κB p65 in myocardial tissues were significantly elevated(P<0.05, P<0.01). Compared with the model group, mice in the Shenfu Injection and TAK-242 groups showed elevated LVEF, LVFS, IL-10, and Arg-1 levels, and decreased LVIDd, LVIDs, NT-proBNP, TNF-α, and IL-6 levels(P<0.05, P<0.01); the cardiac F4/80+CD11b+(macrophage) and M1-F4/80+ CD86+ values were significantly down-regulated, while M2-F4/80+CD163~+ values were increased(P<0.05, P<0.01); and the mRNA and protein expressions of TLR4, MyD88, IKKα, and NF-κB p65 in myocardial tissues were notably decreased(P<0.05, P<0.01). CHF mice have an imbalance of M1/M2 macrophage polarization, with M1-type macrophages predominating. Shenfu Injection promotes macrophage polarization towards M2, inhibits M1-type macrophage activation, and attenuates inflammatory responses in heart failure by regulating the TLR4/NF-κB signaling pathway.
本研究旨在探讨参附注射液对慢性心力衰竭(CHF)小鼠的治疗作用及其对巨噬细胞极化的影响。将C57BL/6J小鼠随机分为正常组和模型组。通过腹腔注射异丙肾上腺素(ISO,7.5mg·kg⁻¹,28天)建立CHF模型。通过评估心功能和N末端脑钠肽前体(NT-proBNP)来确定建模是否成功。将建模后的小鼠随机分为模型组、参附注射液组和TAK-242组,并腹腔注射相应药物15天。使用超声心动图评估心功能。采用苏木精-伊红(HE)染色检测病理形态学。采用酶联免疫吸附测定(ELISA)检测血清NT-proBNP、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、IL-10和精氨酸酶1(Arg-1)的值。应用流式细胞术检测心脏巨噬细胞的相对含量和M1/M2极化。采用定量聚合酶链反应(qPCR)和蛋白质印迹法检测Toll样受体4(TLR4)/核因子-κB(NF-κB)通路相关mRNA和蛋白质表达的变化。与正常组相比,模型组小鼠的左心室射血分数(LVEF)和左心室短轴缩短率(LVFS)值较低,左心室内径舒张末期(LVIDd)、左心室内径收缩末期(LVIDs)、NT-proBNP、TNF-α和IL-6值较高(P<0.01);心脏组织中巨噬细胞数量增加(P<0.05),M1-F4/80⁺CD86⁺值升高(P<0.01),而M2-F4/80⁺CD163⁺值降低(P<0.05);心肌组织中TLR4、髓样分化因子88(MyD88)、IκB激酶α(IKKα)和NF-κB p65的mRNA和蛋白质表达显著升高(P<0.05,P<0.01)。与模型组相比,参附注射液组和TAK-242组小鼠的LVEF、LVFS、IL-10和Arg-1水平升高,LVIDd、LVIDs、NT-proBNP、TNF-α和IL-6水平降低(P<0.05,P<0.01);心脏F4/80⁺CD11b⁺(巨噬细胞)和M1-F4/80⁺CD86⁺值显著下调,而M2-F4/80⁺CD163⁺值升高(P<0.05,P<0.01);心肌组织中TLR4、MyD88、IKKα和NF-κB p65的mRNA和蛋白质表达显著降低(P<0.05,P<0.01)。CHF小鼠存在M1/M2巨噬细胞极化失衡,以M1型巨噬细胞为主。参附注射液通过调节TLR4/NF-κB信号通路促进巨噬细胞向M2极化,抑制M1型巨噬细胞活化,减轻心力衰竭中的炎症反应。
Zhongguo Zhong Yao Za Zhi. 2024-7
Zhongguo Zhong Yao Za Zhi. 2022-10
Zhongguo Zhong Yao Za Zhi. 2024-7
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021-10
Zhongguo Zhong Yao Za Zhi. 2024-1
Zhongguo Zhong Yao Za Zhi. 2023-12
Front Pharmacol. 2024-7-18